Walgreens Boots Alliance
Explore Walgreens Boots Alliance
Core profile pages, annual revenue records, and related research hubs for this company.
Acquisitions
4
Total Acquisitions
$9.6B
Disclosed Deal Value
2025
Move WBA into private ownership for a deeper restructuring outside public-market pressure.
WBA shares ceased trading on Nasdaq and Walgreens became a private standalone company.
Walgreens is now led by Mike Motz as a private pharmacy and retail turnaround platform.
2021
$5.2B
Build a primary-care clinic platform linked to Walgreens stores.
The strategy consumed capital and created major impairment pressure as clinic economics disappointed.
Walgreens has shifted away from broad clinic expansion and back toward core pharmacy execution.
2017
$4.4B
Expand the U.S. Walgreens pharmacy footprint after the broader Rite Aid merger attempt was blocked.
The store acquisition increased U.S. scale but also added integration and footprint rationalization work.
Store productivity and closure decisions remain part of the private-company turnaround.
2014
Combine Walgreens with the Boots pharmacy and health-and-beauty platform to create Walgreens Boots Alliance.
The deal added international pharmacy, beauty retail, and wholesale distribution scale, but also made the public company more complex.
The combined WBA structure ended as a public-company story when Sycamore completed the take-private in 2025 and Walgreens began operating as a private standalone company.
The strategy is operational repair: focus on pharmacy, improve store contribution, close weak locations, reduce complexity, preserve customer trust, and use private ownership to restructure the company outside quarterly public-market pressure.
Walgreens earns from prescription pharmacy, front-end retail, immunizations, health services, specialty pharmacy relationships, loyalty-driven retail activity, and partnerships across the pharmacy ecosystem. The current private-company model is narrower and more operationally focused than the old public WBA story. Management is emphasizing core pharmacy execution, store productivity, cost discipline, and selective healthcare services after the VillageMD strategy destroyed significant value.
The most consequential recent deal is Sycamore Partners acquisition of Walgreens Boots Alliance in 2025.
Walgreens used deals for scale, healthcare adjacency, and restructuring options.
Deals changed the company scale and complexity; the 2025 take-private changed its governance and turnaround path.
No. Walgreens also relies on organic product development, operating execution, and customer expansion.